Pyrrolo[3,2-D]pyrimidine derivatives as inducers of human interferon
Compounds of formula (I) and salts thereof: wherein R 1 is hydrogen, methyl or —(CH 2 ) 2 OR 3 , R 2 is methyl or —(CH 2 ) 2 OR 4 , or R 1 and R 2 , together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents; R 3 and R 4 are each independently hydrogen or methyl; and n is an integer having a value of 5 or 6, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment or prevention of various disorders, for example the treatment or prevention of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
1. A compound of formula (I), or a salt thereof:
wherein:
R 1 is hydrogen, methyl or —(CH 2 ) 2 OR 3 ,
R 2 is methyl or —(CH 2 ) 2 OR 4 ,or
R 1 and R 2 , together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents;
R 3 and R 4 are each independently hydrogen or methyl; and
n is an integer having a value of 5 or 6.
2. A compound according to claim 1 , or a salt thereof, wherein R 2 is hydrogen, methyl or —(CH 2 ) 2 OR 3 , and R 2 is methyl or —(CH 2 ) 2 OR 4 .
3. A compound according to claim 1 wherein R 1 and R 2 , together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents.
4. A compound according to claim 1 wherein n is 5.
5. A compound according to claim 1 wherein n is 6.
6. A compound, or a salt thereof, selected from:
2,6-dimethyl-7-(6-(piperidin- 1-yl)hexyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine;
2,6-dimethyl-7-(5-(pyrrolidin-1-yl)pentyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine;
2,2′-((5-(4-amino-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)pentyl)azanediyl)diethanol;
2,2′-((6-(4-amino-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)hexyl)azanediyl)diethanol;
2-((6-(4-amino-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)hexyl)(2-methoxyethyl)amino)ethanol;
7-(6-(bis(2-methoxyethyl)amino)hexyl)-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine;
2-((6-(4-amino-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)hexyl)amino)ethanol;
(3R,5S)-1-(6-(4-amino-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)hexyl)piperidine-3,5-diol;
(3R,5R)-1-(6-(4-amino-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)hexyl)piperidine-3,5-diol; and
7-(6-(dimethylamino)hexyl)2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine.
7. A compound according to claim 1 , which is in the form of a pharmaceutically acceptable salt.
8. A compound according to claim 1 , which is in the form of a free base.
9. A pharmaceutical composition comprising a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
10. A vaccine composition comprising a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and an antigen or antigen composition.
11. A method of treatment of allergic rhinitis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof.
12. A method of treatment of asthma, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof.
13. A compound according to claim 6 , which is in the form of a pharmaceutically acceptable salt.
14. A compound according to claim 6 , which is in the form of a free base.
15. A pharmaceutical composition comprising a compound as defined in claim 6 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
16. A vaccine composition comprising a compound as defined in claim 6 , or a pharmaceutically acceptable salt thereof, and an antigen or antigen composition.
17. A method of treatment of allergic rhinitis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a compound as defined in claim 6 , or a pharmaceutically acceptable salt thereof.
18. A method of treatment of asthma, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a compound as defined in claim 6 , or a pharmaceutically acceptable salt thereof.